Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies: an Open-label, Single Arm, Phase IV Study

Trial Profile

Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies: an Open-label, Single Arm, Phase IV Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Breast cancer; Cervical cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top